Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ANEB Anebulo Pharmaceuticals	$1.46 +2.8%	$1.17	$0.80 ▼ $3.08	$59.98M	-1.15	18,245 shs	24,507 shs
BMEA Biomea Fusion	$1.81 -9.0%	$1.94	$1.29 ▼ $13.07	$68.00M	-0.23	1.14 million shs	4.50 million shs
CLSD Clearside Biomedical	$0.77 -5.1%	$0.83	$0.70 ▼ $2.00	$59.84M	2.06	360,219 shs	282,299 shs
HPPI HedgePath Pharmaceuticals	$0.05 -2.1%	$0.05	$0.04 ▼ $0.32	$17.37M	-1.16	19,283 shs	4,000 shs

7 Stocks to Buy And Hold Forever

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ANEB Anebulo Pharmaceuticals	0.00%	-5.19%	+46.00%	+12.31%	-46.52%
BMEA Biomea Fusion	0.00%	0.00%	+25.69%	-15.02%	-59.78%
CLSD Clearside Biomedical	0.00%	-8.31%	+1.32%	-16.11%	-40.77%
HPPI HedgePath Pharmaceuticals	0.00%	+8.06%	-4.09%	-19.14%	-40.63%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ANEB Anebulo Pharmaceuticals	2.2175 of 5 stars	3.5	3.0	0.0	0.0	2.0	1.7	0.0
BMEA Biomea Fusion	2.6863 of 5 stars	3.6	1.0	0.0	0.0	3.2	2.5	0.6
CLSD Clearside Biomedical	1.8017 of 5 stars	3.5	3.0	0.0	0.0	2.2	0.0	0.0
HPPI HedgePath Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ANEB Anebulo Pharmaceuticals	3.00	Buy	$5.50	276.71% Upside
BMEA Biomea Fusion	3.18	Buy	$21.40	1,082.32% Upside
CLSD Clearside Biomedical	3.00	Buy	$4.75	516.88% Upside
HPPI HedgePath Pharmaceuticals	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest HPPI, CLSD, ANEB, and BMEA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/24/2025	BMEA Biomea Fusion	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$16.00
6/13/2025	BMEA Biomea Fusion	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$16.00
6/3/2025	BMEA Biomea Fusion	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$7.00
6/2/2025	BMEA Biomea Fusion	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
5/23/2025	CLSD Clearside Biomedical	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$6.00 ➝ $5.00
5/16/2025	CLSD Clearside Biomedical	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$5.00 ➝ $5.00
5/15/2025	ANEB Anebulo Pharmaceuticals	Maxim Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$6.00 ➝ $3.00
5/15/2025	BMEA Biomea Fusion	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$16.00 ➝ $16.00
5/15/2025	CLSD Clearside Biomedical	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$4.00 ➝ $3.00
5/6/2025	BMEA Biomea Fusion	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$40.00 ➝ $18.00
5/6/2025	BMEA Biomea Fusion	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$16.00 ➝ $16.00

(Data available from 6/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ANEB Anebulo Pharmaceuticals	N/A	N/A	N/A	N/A	$0.15 per share	N/A
BMEA Biomea Fusion	N/A	N/A	N/A	N/A	$1.42 per share	N/A
CLSD Clearside Biomedical	$1.66M	36.05	N/A	N/A	($0.51) per share	-1.51
HPPI HedgePath Pharmaceuticals	N/A	N/A	N/A	N/A	($0.01) per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ANEB Anebulo Pharmaceuticals	-$8.20M	-$0.26	N/A	∞	N/A	N/A	-90.11%	-84.53%	N/A
BMEA Biomea Fusion	-$138.43M	-$3.55	N/A	N/A	N/A	N/A	-197.71%	-134.84%	7/30/2025 (Estimated)
CLSD Clearside Biomedical	-$34.35M	-$0.41	N/A	N/A	N/A	-818.57%	N/A	-114.23%	8/11/2025 (Estimated)
HPPI HedgePath Pharmaceuticals	-$4.55M	N/A	0.00	∞	N/A	N/A	N/A	-246.03%	N/A

Latest HPPI, CLSD, ANEB, and BMEA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/14/2025	Q1 2025	CLSD Clearside Biomedical	-$0.12	-$0.11	+$0.01	-$0.11	$0.20 million	$2.33 million
5/13/2025	Q3 2025	ANEB Anebulo Pharmaceuticals	-$0.05	-$0.04	+$0.01	-$0.04	N/A	N/A
5/5/2025	Q1 2025	BMEA Biomea Fusion	-$0.84	-$0.80	+$0.04	-$0.80	N/A	N/A
3/31/2025	Q4 2024	BMEA Biomea Fusion	-$1.00	-$0.81	+$0.19	-$0.81	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ANEB Anebulo Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
BMEA Biomea Fusion	N/A	N/A	N/A	N/A	N/A
CLSD Clearside Biomedical	N/A	N/A	N/A	N/A	N/A
HPPI HedgePath Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ANEB Anebulo Pharmaceuticals	N/A	25.29	25.29
BMEA Biomea Fusion	N/A	2.25	2.25
CLSD Clearside Biomedical	N/A	3.19	3.19
HPPI HedgePath Pharmaceuticals	N/A	6.76	6.76

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ANEB Anebulo Pharmaceuticals	28.40%
BMEA Biomea Fusion	96.72%
CLSD Clearside Biomedical	18.75%
HPPI HedgePath Pharmaceuticals	N/A

Insider Ownership

Company	Insider Ownership
ANEB Anebulo Pharmaceuticals	80.60%
BMEA Biomea Fusion	18.42%
CLSD Clearside Biomedical	6.20%
HPPI HedgePath Pharmaceuticals	4.80%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ANEB Anebulo Pharmaceuticals	4	41.08 million	7.97 million	Not Optionable
BMEA Biomea Fusion	50	37.57 million	30.65 million	Optionable
CLSD Clearside Biomedical	30	77.71 million	72.89 million	Optionable
HPPI HedgePath Pharmaceuticals	1	370.45 million	N/A	Not Optionable

HPPI, CLSD, ANEB, and BMEA Headlines

Recent News About These Companies

Eagle Pharmaceuticals Inc.

February 17, 2024 | wsj.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

HPPI, CLSD, ANEB, and BMEA Company Descriptions

Anebulo Pharmaceuticals NASDAQ:ANEB

$1.46 +0.04 (+2.82%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$1.44 -0.02 (-1.71%)

As of 06/27/2025 04:04 PM Eastern

Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing solutions for people suffering from acute cannabinoid intoxication (ACI) and substance addiction. The company's lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist, which is in a Phase II clinical trial to address the unmet medical need for a specific antidote for ACI. Anebulo Pharmaceuticals, Inc. was incorporated in 2020 and is based in Lakeway, Texas.

Biomea Fusion NASDAQ:BMEA

$1.81 -0.18 (-9.05%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$1.87 +0.06 (+3.37%)

As of 04:51 AM Eastern

Biomea Fusion, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, a covalent inhibitor of menin for treating patients with liquid and solid tumors and type 2 diabetes. The company was incorporated in 2017 and is headquartered in Redwood City, California.

Clearside Biomedical NASDAQ:CLSD

$0.77 -0.04 (-5.06%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$2.00 +1.23 (+159.74%)

As of 04:00 AM Eastern

Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. It offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase IIb clinical trial to treat wet AMD. The company has a collaboration with Bausch Health, Arctic Vision, REGENXBIO, Inc., BioCryst Pharmaceuticals, Inc., and Aura Biosciences. Clearside Biomedical, Inc. was incorporated in 2011 and is headquartered in Alpharetta, Georgia.

HedgePath Pharmaceuticals OTCMKTS:HPPI

$0.05 0.00 (-2.09%)

As of 06/27/2025

HedgePath Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for patients with cancers and non-cancerous proliferation disorders in the United States. It primarily focuses on the development of therapies for skin, lung, and prostate cancers. The company's Hedgehog signaling pathway is a primary regulator of cellular processes in vertebrates, including stem cell maintenance, cell differentiation, tissue polarity, and cell proliferation. It also develops super bioavailability (SUBA)-itraconazole oral capsules for patients with basal cell carcinoma nevus syndrome. SUBA-Itraconazole is a patented itraconazole formulation that enhances the absorption of itraconazole to enhance the bioavailability of orally administered drugs that are poorly soluble. The company was founded in 1992 and is headquartered in Tampa, Florida. HedgePath Pharmaceuticals, Inc. is a subsidiary of Mayne Pharma Ventures Pty Ltd.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time